INVA
Innoviva, Inc.
$21.89
+0.15 (+0.69%)
At close · Jul 15
Market Cap
$1.63B
Shares
73,808,749
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.89
Open$21.77
Day$21.56–22.04
52W$16.52–25.15
Avg vol 30d888K
Short int6.6M · 9.0% float · 6.8d
Short vol47%
Last earningsMay 8, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15.7 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
−2%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
62%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+12%
trailing
YTD return
+10%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
13 of 285 funds reported for Jun 30 · net +93.6K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.00% of float · ▲ +0.7% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
285 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+63%
Y/Y
Gross margin
142%
contracting
EPS growth
+817%
Y/Y
Free cash flow
$195.8M
Valuation
P/E 3.5
below peers
Buyback
$125.0M
remaining
Balance sheet
$197.3M
net debt
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
62%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $22 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
13 of 285 funds reported for Jun 30 · net +93.6K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.00% of float · ▲ +0.7% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
285 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $17
Now $22 · 62%
52-wk high $25
vs 200-day avg +3%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INVA
this stock
Innoviva, Inc.
|
$1.63B | +9.5% | +62.6% | 3.5 | 9.0% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INVA | -2.4% | -2.4% | +11.7% | -3.6% | +9.5% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -3.7% | -2.2% | +1.6% | -4.7% | -1.2% |
Capital returns
Buyback program
· as of Nov 3, 2025
Authorized
$125.00M
Spent (derived)
$0
Remaining
$125.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1080014
CUSIP
45781M101
13F (30d)
14 filings
14 filers
Visit website
Investor relations